# A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer.

Source: https://onco.cc/trials/nct07672236/  
OnCo record `nct07672236` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of BupiZenge 25 mg in advanced solid tumours, run by OncoZenge AB, now recruiting.

## Summary

A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck Cancer. is a phase 3 interventional study registered as NCT07672236 by OncoZenge AB, with 150 participants planned, started 2026-07-07 and due to reach its primary completion in 2026-12-23. Interventions recorded: BupiZenge 25 mg and Lidocaine viscous 2%.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07672236
- Phase: 3
- Setting: A Randomized, Open-label, Phase III Trial to Assess the Efficacy and Safety of BupiZenge Compared to Lidocaine for Pain Associated With Oral Mucositis in Head and Neck Cancer
- Sponsor: OncoZenge AB
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07672236: https://clinicaltrials.gov/study/NCT07672236

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07672236.json